Near-infrared investigations of novel anti-HIV tenofovir liposomes

AAPS Journal

Volumn 12, Issue 2, 2010, Pages 202-214

  Zidan, Ahmed S ^a,c   Spinks, Crystal ^a,b   Fortunak, Joseph ^b   Habib, Muhammad ^b   Khan, Mansoor A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HOWARD UNIVERSITY   (United States)

^c Zagazig University   (Egypt)

Author keywords

Characterization; Chemical imaging; Liposomes; Near infrared; Tenofovir

Indexed keywords

LIPOSOME; OCTADECYLAMINE; PHOSPHOLIPID; TENOFOVIR;

ACCURACY; ARTICLE; CALIBRATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; EXCIPIENT COMPATIBILITY; FILM; IMAGE ANALYSIS; INFRARED SPECTROSCOPY; NEAR INFRARED SPECTROSCOPY; PARTICLE SIZE; SLOW DRUG RELEASE; X RAY DIFFRACTION; ZETA POTENTIAL;

ADENINE; AMINES; ANTI-HIV AGENTS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; ELECTROCHEMISTRY; EXCIPIENTS; FREEZE DRYING; LEAST-SQUARES ANALYSIS; LIPOSOMES; PARTICLE SIZE; PHOSPHOLIPIDS; PHOSPHONIC ACIDS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SPECTROSCOPY, NEAR-INFRARED; ULTRACENTRIFUGATION; X-RAY DIFFRACTION;

EID: 77950668247     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9177-1     Document Type: Article

References (41)

1. Clumeck N, De Wit S. Update on highly active antiretroviral therapy: progress and strategies. Biomed Pharmacother. 2000;54:7-12. (Pubitemid 30126193)
2. Kaufmann GR, Cooper GA. Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. Curr Opin Microbiol. 2000;3:508-514
3. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJM. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 2002;54(1):37-45. (Pubitemid 34219173)
4. Cihlar T, Bischofberger N. PMEA and PMPA: acyclic nucleoside phosphonates with potent anti-HIV activity. In: Van der Goot H, editor. Trends in drug research II. Amsterdam: Elsevier; 1998. p. 105-116
5. Schooley R, Myers R, Ruane P, Beall G, Lampiris H, Miller M, Mills R, McGowan I. Tenofovir disoproxil fumarate (TDF) for the treatment of antiretroviral experienced patients. A double-blind placebo-controlled study. 40th International Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada; 2000.
6. Barditch-Crovo P, Deeks S, Collier A, Safrin S, Coakley D, Miller MD, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739 (Pubitemid 32906664)
7. Pozniak A. Tenofovir: what have over 1 million years of patient experience taught us? Int J Clin Practice. 2008;62:1285-1293 (Pubitemid 351977619)
8. Sosnik A, Chiappetta DA, Carcaboso ÁM. Drug delivery systems in HIV pharmacotherapy: what has been done and the challenges standing ahead. J Control Release. 2009;138(1):2-15.
9. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997;154:123-140 (Pubitemid 27351317)
10. Desormeaux A, Bergeron MG. Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection. J Drug Target. 1998;6:1-15. (Pubitemid 28499585)
11. Jin SX, Bi DZ, Wang J, Wang YZ, Hu HG, Deng YH. Pharmacokinetics and tissue distribution of zidovudine in rats following intravenous administration of zidovudine myristate loaded liposomes. Pharmazie. 2005;60:840-843 (Pubitemid 41704161)
12. Ojewole E, Mackraj I, Naidoo P, Govender T. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm. 2008;70(3):697-710.
13. Vredenbregt M, Caspers P, Hoogerbrugge R, Barends D. Choice and validation of a near infrared spectroscopic application for the identity control of starting materials. Practical experience with the EU draft Note for Guidance on the use of near infrared spectroscopy by the pharmaceutical industry and the data to be forwarded in part II of the dossier for a marketing authorization. Eur J Pharm Biopharm. 2003;56:489-499 (Pubitemid 37346522)
14. Trafford AD, Jee RD,Moffat AC, Graham P. A rapid quantitative assay of intact paracetamol tablets by reflectance near-infrared spectroscopy. Analyst. 1999;124:163-167 (Pubitemid 29092396)
15. Bakeev K. Near-infrared spectroscopy as a process analytical tool-part I: laboratory applications. Spectroscopy. 2003;18:32-35 (Pubitemid 41100900)
16. Bakeev K. Near-infrared spectroscopy as a process analytical tool: part II: at-line and on-line applications and implementation strategies. Spectroscopy. 2004;19:39-42. (Pubitemid 41100982)
17. Guidance for industry, "PAT-A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance" (2003). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070305.pdf.
18. Roggo Y, Roeseler C, Ulmschneider M. Near infrared spectroscopy for qualitative comparison of pharmaceutical batches. J Pharm Biomed Anal. 2004;36:777-786 (Pubitemid 39469417)
19. Kuny T, Schatz C, Ulmschneider M, Marrer S, Leuenberger H. Non-destructive dissolution testing correlation. Dissolution Technol. 2003;10:22-28
20. Gendrin C, Roggo Y, Collet C. Content uniformity of pharmaceutical solid dosage forms by near infrared hyperspectral imaging: a feasibility study. Talanta. 2007;73(4):733-741 (Pubitemid 47379768)
21. Saarinen-Savolainen P, Järvinen T, Taipale H, Urtti A. Method for evaluating drug release from liposomes in sink conditions. Int J Pharm. 1997;159:27-33. (Pubitemid 28062807)
22. Ausborn M, Schreier H, Brezesinski G, Fabian H, Meyer HW, Nuhn P. The protective effect of free and membrane-bound cryoprotectants during freezing and freeze-drying of liposomes. J Control Release. 1994;30(2):105-116 (Pubitemid 24215429)
23. Cho S, Chung H, Lee Y. Simple and fast near-infrared spectroscopic analysis of hydroxyl number of polyol using a disposable glass vial. Microchem J. 2005;80:189-193 (Pubitemid 40517179)
24. Savitzky A, Golay MJE. Smoothing and differentiation of data by simplified least squares procedures. Anal Chem. 1964;36:1627-1639
25. Mainardes RM, Silva LP. Drug delivery systems: past, present, and future. Curr Drug Targets. 2004;5:449-455 (Pubitemid 38807819)
26. Heurtault B, Saulnier P, Pech B, Proust J, Benoit J. Physicochemical stability of colloidal lipid particles. Biomaterials. 2003; 24:4283-4300 (Pubitemid 36814076)
27. Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul. 1995;12:229-246
28. Deleers M, Guilmin T, Vandenbranden M, Ruysschaert JM. Thermotropic properties of dipalmitoyl phosphatidyl choline stearylamine liposomes. Pharmacol Res Commun. 1982;14 (4):333-339 (Pubitemid 12007170)
29. Deleers M, Malaisse WJ. Ionophore-mediated calcium exchange diffusion in liposomes. Biochem Biophys Res Commun. 1980;95 (2):650-657
30. Zschörnig O, Arnold K, Richter W, Ohki S. Dextran sulfatedependent fusion of liposomes containing cationic stearylamine. Chem Phys Lipids. 1992;63(1-2):15-22. (Pubitemid 23031863)
31. Hope MJ, Cullis PR. Lipid asymmetry induced by transmembrane pH gradients in large unilamellar vesicles. J Biol Chem. 1987;262:4360-4366
32. Hope MJ, Redelmeier TE, Wong KF, Rodrigueza W, Cullis PR. Phospholipid asymmetry in large unilamellar vesicles induced by transmembrane pH gradients. Biochemistry. 1989;28:4181-4187 (Pubitemid 19141617)
33. Harrigan PR, Wong KF, Redelmeier TE, Wheeler JJ, Cullis PR. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim Biophys Acta. 1993;1149:329-338
34. Murray SW, Jeffery JW, Marcel BB, Lawrence DM. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochimica et Biophysica Acta (BBA)-Biomembranes. 1995;1238(2):147-155
35. Heigl N, Petter CH, Lieb M, Bonn GK, Huck CW. Near-infrared reflection spectroscopy and partial least squares regression for determining the total carbon coverage of silica packings for liquid chromatography. Vibr Spectrosc. 2009;49(2):155-161
36. Smith RC, Baker KS. Optical properties of the clearest natural waters (200-800 nm). Appl Opt. 1981;20:177-184
37. Droge B. Asymptotic optimality of full cross-validation for selecting linear regression models. Statistics and Probability Letters. 1999;44(4):351-357
38. Droge B. Some comments on cross-validation. In: Härdle W, Schimek MG, editors. Statistical theory and computational aspects of smoothing. Heidelberg: Physica; 1996. p. 178-199
39. Shenk J, Workman S, Westerhaus JJ. Application of NIR spectroscopy to agricultural products. In: Burns DA, Ciurczak EW, editors. Handbook of near infrared-analysis. New York: Marcel Dekker; 1992. p. 383-431.
40. Otsuka M. Comparative particle size determination of phenacetin bulk powder by using Kubelka-Munk theory and principal component regression analysis based on near-infrared spectroscopy. Powder Technol. 2004;141(3):244-250 (Pubitemid 38728993)
41. Lyon RC, Lester DS, Lewis EN, Lee E, Yu LX, Jefferson EH, et al. Near-infrared spectral imaging for quality assurance of pharmaceutical products: analysis of tablets to assess powder blend homogeneity. AAPS PharmSciTech. 2002;3(3):E17. (Pubitemid 41086116)